Calithera Biosciences Stock Price - CALA

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Calithera Biosciences Inc CALA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.09 -2.15% 4.10 0.00 0.00 0.00 4.19 19:00:00
Bid Price Ask Price Spread Spread % News
3.86 4.50 0.64 14.22% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,213 151,499 $ 4.06 $ 614,830 266,985 3.43 - 6.90
Last Trade Time Type Quantity Stock Price Currency
16:00:03 formt 100 $ 4.10 USD

Calithera Biosciences Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 220.48M 53.77M $ -54.63M -1.49 - 53.56M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Calithera Biosciences News

Loading Messages....

Latest CALA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CALA Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week4.14.413.944.2181274k0-
1 Month4.014.413.744.0176244k0.092.24%
3 Months3.814.573.434.0305344k0.297.61%
6 Months6.496.93.434.6263306k-2.39-36.83%
1 Year4.76.93.434.8242288k-0.6-12.77%
3 Years2.9620.052.28.9893472k1.1438.51%
5 Years10.2233.482.29.1527401k-6.12-59.88%

Calithera Biosciences Description

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.